|
Overview
| The G.O.T Summit Highlights
|
• Expanded Networking Opportunities
• Attend all 4 conferences at The G.O.T. Summit and Save!
• Hear Presentations from over 80 Scientists
• Over 25 Exhibitors Showcasing the Latest Technology and Services |
| Featured Speakers
|
Dr. George Church, Harvard Medical School
Dr. Ellen G. Feigal, TGen
Dr. Stacey Gabriel, Broad Institute
Dr. John N. Weinstein, NCI |
| DISTINGUISHED
FACULTY |
Mr. John S. Abrams, Launch Capacity, Inc.
Dr. Andrew I. Brooks, University of Rochester
Dr. Eugene L. Brown, Wyeth Research
Dr. George M. Church, Harvard Medical School
Dr. Jannine Cody, University of Texas Health Science Center
Dr. Richard Einstein, ExonHit Therapeutics, Inc.
Dr. Ellen G. Feigal, TGen
Dr. Stacey Gabriel, Broad Institute
Dr. Guillermo Garcia-Cardena, Harvard Medical School
Dr. Angelique H. Habis, Applied Biosystems
Dr. Stephen M. Hewitt, NCI
Dr. Anthony Koleske, Yale University
Dr. Allen Lamb, Genzyme Genetics
Dr. Charles Lee, Harvard Medical School
Dr. Neil Dey, BioImagene, Inc.
Dr. Estelle Marrer, Novartis Pharma AG
Dr. Mansoor Mohammed, Quest Diagnostics, Inc.
Dr. David L. Rimm, Yale University School of Medicine
Dr. Charles Rogler, Albert Einstein College of Medicine
Dr. Jeffrey S. Ross, Millennium Pharmaceuticals, Inc./Albany Medical College
Dr. Mark Rubin, Dana-Farber/Harvard Cancer Center
Dr. Mary Satterfield, NIST
Dr. Steve Scherer, The Hospital for Sick Children-Toronto
Dr. Lisa Shaffer, Signature Genomic Laboratories, LLC
Dr. Timothy T. Stenzel, Vysis/Abbott Molecular
Dr. Zoltan Szallasi, Harvard Medical School
Dr. John N. Weinstein, NCI
|
The anticipated FDA's Pharmacogenomic Guidance Document holds the promise that 2005 will be an extraordinary year for the advancement of the capabilities of
microarrays. Microarrays build bridges on which biologists and clinicians can meet to understand, diagnose, and treat diseases. The promises of microarrays are:
• rapid access to molecular pathways
• more precise diagnosis and prognosis of diseases
• better understanding of drug action
• better definitions of therapeutic strategies
That, coupled with the FDA's growing interest in the use of microarray-based genomic diagnostic devices, holds a bright future for both researchers developing pharmaceuticals and clinicians performing diagnostics. Optimizing "arrays" depends on carefully assessing your specific purposes. Cambridge Healthech Institute's Microarrays in Medicine: Arrays of Possibilities, will provide practical information and results about new technical developments and specific applications to help determine which arrays are best for your specific application or research need.
Scientific Advisors
Dr. Andrew I. Brooks, University of Rochester
Dr. Mansoor Mohammed, Quest Diagnostics
Dr. Zoltan Szallasi, Harvard Medical School |
For sponsorship information, please contact:
Carol Dinerstein, Business Development Manager
at 781-972-5471, E-mail: dinerstein@healthtech.com
|
